Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-2.14579Keywords:
androgen receptor, clinical prognosis, overall survival, triple negative breast cancerAbstract
Summary. At present, there are no valid prognostic biomarkers in patients with triple negative breast cancer (TNBC) except well known clinical factors such as tumor size, lymph node status, differentiation grade and proliferation rate. Aim: To evaluate the prognostic role of androgen receptor (AR) expression in patients with TNBC. Materials and Methods: The effect of the AR expression level in tumor tissue on overall survival depending on clinical, histological and immunohistochemical characteristics of the tumor was evaluated in 116 patients with metastatic TNBC. Results: The independent prognostic value of AR expression in patients with TNBC of different stages was shown. The median overall survival was higher in patients with AR-positive tumors compared with AR-negative tumors (57 months vs 27 months, p < 0.0001). Five-year survival since diagnosis in the group with AR-positive TNBC was 47.6 ± 8.3% vs 20.0 ± 5.3% in the group with AR-negative TNBC (p < 0.05). Conclusions: The results of our study indicate a favorable impact of AR expression on the overall survival of TNBC patients.
References
Krylov A Yu, Krylov Yu V. Androgens and breast cancer (literature review). Vestnik Vitebsk Gos Med Univ 2015; 14: 5–15 (in Russian).
Gerratana L, Basile D, Buono G, et al. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treat Rev 2018; 68: 102–10.
Giovannelli P, DiDonato M, Galasso G, et al. The androgen receptor in breast cancer. Front Endocrinol 2018; 9: 492.
Gucalp A, Traina TA. Targeting the androgen receptor in triple-negative breast cancer. Curr Probl Cancer 2016; 40: 141–50.
Niemeier LA, Dabbs DJ, Beriwal S, et al. Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2010; 23: 205–12.
Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750–67.
Kim Y, Jae E, Yoon M. Influence of androgen receptor expression on the survival outcomes in breast cancer: A meta-analysis. Breast Cancer 2015; 18: 134–42.
Choi JE, Kang SH, Lee SJ, et al. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol 2015; 22: 82–9.
Wang C, Pan B, Zhu H, et al. Prognostic value of androgen receptor in triple negative breast cancer: a meta-analysis. Oncotarget 2016; 7: 46482–91.
Collins LC, Cole KS, Marotti JD, et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses’ Health Study. Mod Pathol 2011; 24: 924–31.
Barton VN, D’Amato NC, Gordon MA, et al. Androgen receptor biology in triple negative breast cancer: a case for classification as AR+ or quadruple negative disease. Horm Cancer 2015; 6: 206–13.
Rahim B, O’Regan R. AR signaling in breast cancer. Cancers (Basel) 2017; 9: 21.
Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly (ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 2012; 13: 411–24.
Luo J, Jin J, Yang F, et al. The correlation between PARP1and BRCA1 in AR positive triple-negative breast cancer. Int J Biol Sci 2016; 12: 1500–10.
Gong Y, Wei W, Wu Y, et al. Expression of androgen receptor in inflammatory breast cancer and its clinical relevance. Cancer 2014; 120:1775–9.
Asano Y, Kashiwagi S, Goto G, et al. Expression and clinical significance of androgen receptor in triple-negative breast cancer. Cancers 2017; 9: 4.
Qu Q, Mao Y, Fei X, et al. The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS One 2013; 8: e82650.
Kim Y, Jae E, Yoon M, et al. Influence of androgen receptor expression on the survival outcomes in breast cancer: a meta-analysis. J Breast Cancer 2015; 18: 134.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
